Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy

Kim, Jae Hyun; Hong, Juhyeong; Lee, Jieun; Lahiji, Shayan Fakhraei; Kim, Yong Hee

doi:10.1016/j.jconrel.2021.02.002

Cited by 42 publications

(25 citation statements)

References 248 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increasing number of reports showed that tumor progression was dependent upon interactions in the TME between tumor cells and stromal cells such as immune cells, fibroblasts, and endothelial cells ( Kumari et al, 2021 ). It is well-known that immune cells affect each other by secreting different cytokines as well ( Krejcik et al, 2016 ; Han et al, 2021a ; Kim et al, 2021 ). Macrophages are the key regulators of homeostatic tissue and the TME ( Ruffell and Coussens, 2015 ).…”

Section: Resultsmentioning

confidence: 99%

Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis

Liu

Shen

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Ovarian cancer (OC) is the most lethal gynecological malignancy, in which chemoresistance is a crucial factor leading to the poor prognosis. Recently, immunotherapy has brought new light for the treatment of solid tumors. Hence, as a kind of immunologically active cancer, it is reasonably necessary to explore the potential mechanism between immune characteristics and cisplatin resistance in OC. Our study focused on the important role of cisplatin resistance-related lncRNAs on mediating the OC tumor immune microenvironment (TIME) using an integrative analysis based on the Cancer Genome Atlas (TCGA) database. First, the cisplatin resistance-related differentially expressed lncRNAs (DELs) and mRNAs (DEMs) were preliminarily screened to construct a DEL–DEM co-expression network. Next, the protein–protein interaction (PPI) network and pivot analysis were performed to reveal the relevance of these lncRNAs with tumor immune response. Second, the novel lncRNA CTD-2288O8.1 was identified as a key gene for the OC cisplatin resistance formation by qRT-PCR and survival analysis. Gain- and loss-of-function assays (Cell Counting Kit-8 (CCK-8) assay, wound-healing scratch assay, transwell assay, and colony formation assay) further verified the activity of CTD-2288O8.1 in OC progression as well. Third, gene set enrichment analysis (GSEA) was applied along with the correlation analyses of CTD-2288O8.1 with ImmuneScore, tumor-infiltrating immune cells (TICs), and immune inhibitory checkpoint molecules, illustrating that CTD-2288O8.1 was strongly associated with the TIME and has the potential to predict the effect of OC immunotherapy. In addition, basic experiments demonstrated that the expression of CTD-2288O8.1 impacted the EGFR/AKT signal pathway activity of OC tumor cells. Of greater significance, it promoted the M2 polarization of macrophage, which is a type of the most important components of the TIME in solid tumor. Taking together, our study revealed cisplatin resistance-related lncRNAs closely linked with tumor immunity in OC, underscoring the potential mechanism of the TIME in conferring cisplatin resistance, which provided the research basis for further clinical treatment. CTD-2288O8.1 was identified to mediate cisplatin resistance and affect the response of immunotherapy, which could serve as a promising biomarker for guiding clinical treatment and improving prognosis in OC.

show abstract

Section: Resultsmentioning

confidence: 99%

Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis

Liu

Shen

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Many large clinical trials have shown that immune checkpoint blockade (ICB) therapy might benefit chemotherapy resistance patients in ESCC, even as an individualized agent in palliative treatment [ 21 , 22 ]. A related study found that tumor microenvironment component activity and associated therapeutic strategies could provide insights into the development of combination therapies for immune checkpoint blockade [ 23 ]. Therefore, we evaluated both MAOP1 and immune checkpoints in terms of clinical applicability.…”

Section: Discussionmentioning

confidence: 99%

MAIP1-Related Tumor Immune Infiltration: As a Potential Prognostic Biomarker for Esophageal Cancer

Gan

Lin

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

Background. Esophageal cancer (EC), a common malignant tumor of digestive tract, is also one of the most deadly cancers. Accumulating studies have shown that the initiating and progressing multiple human diseases were closely related to the expression of MAIP. However, the specific roles and mechanisms of MAIP1 in EC remain incompletely defined. Purpose. This study aims to determine the clinical significance of MAIP1 in EC and explores its potential molecular mechanisms regulating tumor immune infiltration. Methods. We obtained RNA-seq datasets and corresponding clinical data for EC patients from the Cancer Genome Atlas (TCGA) database via the UCSC Xena browser to extract MAIP1 expression and plot survival curves to determine their prognosis. Based on the differential expression of MAIP1, EC patients were divided into high and low group to investigate the mechanism of MAIP1 in EC. In addition, the single sample gene set enrichment analysis (ssGSEA) quantified the expression of various immune cell signature marker genes and assessed the degree of immune infiltration in EC. Results. In the TCGA-EC cohort, the overexpression of MAIP1 was observed in tumor tissues compared to normal tissues ( p = 0.0038 ). Overall survival analysis showed that EC patients with the overexpression of MAIP1 presented a lower overall survival and worse prognosis ( p = 0.004 ). Enrichment analysis revealed that the differential genes (DEGs) between high and low group are involved in biological functions such as extracellular matrix and organization extracellular structure. The results of ssGSEA showed that DCs, iDCs, macrophages, mast cells, and NK cells were significantly different in MAIP1high and MAIP1low groups, and all showed high expression in the MAIP1low group. Conclusion. We proposed that MAIP1 overexpression was associated with poor prognosis and tumor immune infiltration in EC. At present, there are few MAIP1-related tumor immune infiltration studies in EC, and further investigation is needed.

show abstract

“…Lung cancer-borne immunological targets like T-lymphocytes, myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and dendritic cells (DCs) may be used to modulate tumor activity by targeting various surface-expressed receptors or by interfering with immune cell-specific pathways ( Jeanson et al, 2019 ; Xia et al, 2019 ; Larionova et al, 2020 ; Yang et al, 2020 ; Yu et al, 2020 ). Nano-drug delivery targeting tumor microenvironment components may enhance the efficacy of immune checkpoint blocking ( Kim et al, 2021 ). Kang et al (2020) confirmed the anti-tumor effect of T-cell-membrane-coated nanoparticles (TCM NPs) in the treatment of lung cancer in an antigenic non-specific way.…”

Section: Biological Receptors and Their Applications For Nanoparticlesmentioning

confidence: 99%

Application of Nanoparticles in the Treatment of Lung Cancer With Emphasis on Receptors

et al. 2022

View full text Add to dashboard Cite

Lung cancer is one of the malignant tumors that has seen the most rapid growth in terms of morbidity and mortality in recent years, posing the biggest threat to people’s health and lives. In recent years, the nano-drug loading system has made significant progress in the detection, diagnosis, and treatment of lung cancer. Nanomaterials are used to specifically target tumor tissue to minimize therapeutic adverse effects and increase bioavailability. It is achieved primarily through two mechanisms: passive targeting, which entails the use of enhanced penetration and retention (EPR) effect, and active targeting, which entails the loading recognition ligands for tumor marker molecules onto nanomaterials. However, it has been demonstrated that the EPR effect is effective in rodents but not in humans. Taking this into consideration, researchers paid significant attention to the active targeting nano-drug loading system. Additionally, it has been demonstrated to have a higher affinity and specificity for tumor cells. In this review, it describes the development of research into active targeted nano-drug delivery systems for lung cancer treatment from the receptors’ or targets’ perspective. We anticipate that this study will help biomedical researchers use nanoparticles (NPs) to treat lung cancer by providing more and novel drug delivery strategies or solid ligands.

show abstract

Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy

Cited by 42 publications

References 248 publications

Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis

Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis

MAIP1-Related Tumor Immune Infiltration: As a Potential Prognostic Biomarker for Esophageal Cancer

Application of Nanoparticles in the Treatment of Lung Cancer With Emphasis on Receptors

Contact Info

Product

Resources

About